此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

GAL-101、2% 眼药水治疗继发于非新生血管性 AMD 的非中心凹地理萎缩的 2 期疗效和安全性研究 (eDREAM)

2026年11月9日 更新者:Galimedix Therapeutics Inc

一项双盲、随机、多中心、平行组、安慰剂对照的 2 期研究,旨在调查 GAL-101(2%)眼药水对继发于非新生血管年龄的非中心凹地理萎缩患者的疗效和安全性相关黄斑变性:EDREAM 研究

Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a small spot in the retina distant from the fovea which is the part of the retina responsible for sharp central vision. The GA grows, and when it reaches the fovea, vision is severely diminished, and details cannot be seen anymore. The purpose of the eDREAM study is to understand if GAL-101 can slow the growth of GA and prevent it from reaching the fovea. GAL-101 is given as eyedrops. eDREAM patients will administer study eyedrops every day. Patients will be assigned by chance (randomly) to receive either eye-drops that contain the new medication, GAL-101, or eyedrops without the active drug (Placebo). Neither patients nor doctors will know which treatment was assigned to each patient until the end of the study.

研究概览

地位

招聘中

详细说明

In this study, if both eyes qualify for the study, the eye with the better BCVA will be defined as the study eye. If both eyes qualify for the study and have identical BCVA, then the eye with higher baseline peripheral retinal degenerations (PRD) will be defined as the study eye. If baseline PRD is identical, then the right eye (OD) will be defined as the study eye. Only the study eye will be dosed with the Investigation Medicinal Product (IMP).

During visits, patients will administer 3 applications of 1 drop of GAL-101 or a matching Placebo that does not contain the active pharmaceutical ingredient (API) at 5-minute intervals (i.e., 1st application, wait 5 minutes, 2nd application, wait 5 minutes, 3rd application), under the supervision of trained and authorized study personnel. In between visits, patients will be instructed to administer 2 applications of 1 drop at 5-minute intervals once a day.

The study will be comprised of a 12- to 24-month treatment period determined individually according to patients' overall placement in global study randomization. All patients will participate at least 12 months of treatment. The visit schedule includes the following: Screening visits (Visit 1a and 1b) for image capture and confirmation of study eligibility by a reading center; Baseline/Randomization/Day 1 (Visit 2); a phone call at 2 weeks; and on-treatment clinic visits for safety and efficacy evaluations at 1 month, 3 months, 6 months, 9 months, and 12 months. Patients will continue to attend on-treatment clinic visits at 3-month intervals after 12 months until the last patient randomized in the study has completed 12 months of study treatment.

研究类型

介入性

注册 (估计的)

110

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Galimedix Inc. c/o Imperial CRS, MD
  • 电话号码:+1 (301) 9179191
  • 邮箱:info@galimedix.com

研究联系人备份

学习地点

      • Tbilisi、乔治亚州、0162
        • 招聘中
        • Akhali Mzera Limited
        • 接触:
        • 首席研究员:
          • Shalva Skhirtladze, MD
      • Tbilisi、乔治亚州、0186
        • 招聘中
        • Caucasus Medical Centre LLC
        • 接触:
        • 首席研究员:
          • Mikheil Omiadze, MD, PhD
      • Yerevan、亚美尼亚、0048
        • 招聘中
        • Ophthalmological Center After S.V. Malayan
        • 接触:
        • 首席研究员:
          • Lilit Voskanyan, MD, PhD
      • Jerusalem、以色列、9112001
        • 招聘中
        • Hadassah Medical Center
        • 接触:
        • 首席研究员:
          • Tareq Jaouni, MD
      • Tel Aviv、以色列、6423906
        • 招聘中
        • Tel Aviv Medical Center
        • 接触:
        • 首席研究员:
          • Omer Trivizki, MD
      • Bonn、德国、53127
        • 招聘中
        • Universitäts-Augenklinik Bonn
        • 首席研究员:
          • Kristina Pfau, MD
        • 接触:
      • Freiburg im Breisgau、德国、79106
        • 招聘中
        • Universitätsklinikum Freiburg Klinik für Augenheilkunde
        • 首席研究员:
          • Hansjuergen Agostini, MD
        • 接触:
      • Hanover、德国、30625
      • Neubrandenburg、德国、17036
        • 招聘中
        • Dietrich Bonhoeffer Klinikum
        • 接触:
        • 首席研究员:
          • Christian Brinkmann, MD
      • Tübingen、德国、72076
        • 招聘中
        • Universitätsklinikum Tübingen, Department für Augenheilkunde.
        • 接触:
        • 首席研究员:
          • Felix Reichel, MD
      • Ulm、德国、89075
        • 尚未招聘
        • UNIVERSITÄTSKLINIKUM ULM Klinik für Augenheilkunde
        • 接触:
        • 首席研究员:
          • Armin Wolf, MD
    • Milano
      • Milan、Milano、意大利、20123
        • 招聘中
        • Medical Retina & Imaging Unit, IRCCS MultiMedica, Ospedale San Giuseppe
        • 接触:
        • 首席研究员:
          • Stela Vujosevic, MD
      • Milan、Milano、意大利、20132
        • 招聘中
        • Unità di Oculistica, IRCCS Ospedale San Raffaele
        • 接触:
        • 首席研究员:
          • Francesco Bandello, MD
    • Roma
      • Roma、Roma、意大利、00184
        • 招聘中
        • UOS Retina Medica, P.O. Britannico, IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia
        • 接触:
        • 首席研究员:
          • Mariacristina Parravanno, MD
      • Bordeaux、法国、33000
        • 招聘中
        • Centre Rétine Gallien
        • 接触:
        • 首席研究员:
          • Eric Fourmaux, MD
      • Lyon、法国、69317
        • 招聘中
        • Hopital de La Croix-Rousse Service D'Ophtalmologie Groupement Hospitalier Nord Hospices Civils de Lyon
        • 接触:
        • 首席研究员:
          • Laurent KODJIKIAN, MD
      • Marseille、法国、13008
        • 招聘中
        • Centre Monticelli Paradis d'Ophtalmologie
        • 接触:
        • 首席研究员:
          • François Devin, MD
      • Paris、法国、75006
        • 招聘中
        • Centre Ophtalmologique Odéon
        • 接触:
        • 接触:
          • Favard, MD
        • 首席研究员:
          • Catherine Favard, MD
      • Tours、法国、37540
        • 招聘中
        • Centre médico-chirurgical de Touraine
        • 接触:
        • 首席研究员:
          • Sam Razavi, MD
      • Kildare、爱尔兰、W91 W535
        • 招聘中
        • UPMC Kildare Hospital Prosperous Rd Clane, Kildare Ireland
        • 首席研究员:
          • Eugene Ng, MD
        • 接触:
      • Waterford、爱尔兰、X91 DH9W
        • 招聘中
        • Institute of Eye Surgery (IOES Waterford)
        • 首席研究员:
          • Eugene Ng, MD
        • 接触:
    • California
      • Beverly Hills、California、美国、90211
        • 招聘中
        • Retina-Vitreous Associates Medical Group
        • 首席研究员:
          • David Boyer, MD
        • 接触:
      • Walnut Creek、California、美国、94598
        • 招聘中
        • Bay Area Retina Associates
        • 首席研究员:
          • Roger Goldberg, MD
        • 接触:
    • Maryland
      • Hagerstown、Maryland、美国、21740
        • 暂停
        • Cumberland Valley Retina Consultants

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

55年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • ≥55 years of age

  • Willing and able to provide written informed consent

  • Willing and able to comply with the study schedule and study assessments

  • Able to successfully administer ophthalmic solution or have an appropriate designee (e.g., family member, health care professional) who can administer ophthalmic solution

  • BCVA of ≥50 letters in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS) chart (i.e., 20/100 Snellen equivalent). Criterion will be confirmed at Baseline

  • Refractive error between +3 and -6 diopters spherical equivalent in the study eye

  • Sufficiently clear ocular media and adequate pupillary dilation to permit quality fundus imaging of the study eye, in the opinion of the Investigator. Criterion will be confirmed at Baseline

  • Diagnosed with non-foveal GA secondary to non-neovascular AMD in the study eye, as confirmed by the reading center

    1. Well-delineated cumulative GA area between 1.25 and 12.0 mm2
    2. If GA is multifocal, at least 1 lesion ≥1.25 mm2
    3. GA lesions must be located outside a ≥100 µm radius from the center point of the fovea (i.e., this area must have intact retinal pigment epithelium [RPE] and outer retina)
    4. GA lesions must be located (partially or wholly) within a 2000 µm radius from the center point of the fovea
    5. GA lesions must be completely located within FAF imaging field (field 2 to 30-degree image centered on the fovea). GA lesion borders must be >300 µm from image edges
    6. GA lesions must be >300 µm from the optic disc and/or peripapillary atrophy
    7. Area of PRD must be cumulatively between 7.25 and 25.0 mm2

Exclusion Criteria:

  1. Presence or history of choroidal neovascularization (CNV). Criterion will be confirmed at Baseline

  2. History of laser therapy in the macular region, regardless of indication

  3. History of herpes zoster

  4. Ophthalmic disease or condition that requires or is likely to require surgery during the study period

  5. GA with cumulative area <1.25 mm2

  6. Any GA lesion within 100 µm radius from the center point of the fovea

  7. Axial length >26 mm

  8. Any ocular disease or condition other than non-neovascular AMD that may, in the opinion of the Investigator, interfere with study assessments, patient adherence to the study schedule, or interpretation of study data (e.g., epiretinal membrane, macular hole, glaucomatous optic neuropathy, etc.)

  9. Intraocular surgery (including cataract extraction and crystalline lens replacement) within 3 months before Visit 1a or yttrium aluminum garnet (YAG) surgery within 2 months before Visit 1a, or planned either during the study period

  10. Use of pegcetacoplan or avacincaptad pegol within 6 months before Visit 1a, or planned use during the study period

  11. Use of any prescription or over-the-counter ophthalmic medication within 1 month before Visit 1a or planned use during the study period

  12. Use of rigid contact lenses within 1 month before Visit 1a or planned use during the study period

    Non-study Eye:

  13. BCVA of <5 letters using ETDRS chart (i.e., 20/800 Snellen equivalent)

    Either Eye:

  14. History of uveitis

  15. GA secondary to any condition other than non-neovascular AMD

  16. History of active ocular infection or inflammation within 3 months before Visit 1a or Baseline. Criterion will be confirmed at Baseline

  17. Underwent investigational treatment for AMD within 6 months before Visit 1a

    General Exclusion Criteria:

  18. History of therapeutic radiation to the cranium

  19. Known allergy or hypersensitivity to the investigational medicinal product (IMP) or any of its excipients

  20. History of malignant disease

  21. Use of hydroxychloroquine within 1 month before Visit 1a, or planned use during the study period

  22. Participated or plan to participate in any other IMP study within 1 month before Visit 1a or during the study period

  23. Use of lutein >10 mg per day or zeaxanthin >2 mg per day within 1 month before Visit 1a, or planned use during the study period

  24. Any medical condition (including mental), in the opinion of the Investigator, that could interfere with study assessments, patient adherence to the study schedule, or interpretation of study data

  25. Screening laboratory values, in the opinion of the Investigator, that make the patient unsuitable for study participation

  26. Pregnant, nursing, or planning a pregnancy during the study. Criterion will be confirmed at Baseline

  27. Unwilling or unable to use an acceptable method of contraception throughout the study if a woman of childbearing potential (WOCBP) or if a sexual partner of a WOCBP

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:GAL-101 ophthalmic solution

Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval

Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval

安慰剂比较:Placebo

Patient will apply daily 2 eye drops ofPlacebo at 5 minutes interval

Patient will apply daily 2 eye drops of Placebo at 5 minutes interval

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in GA lesion size.
大体时间:From baseline to last on-treatment visit (48 up to 96 weeks)

Comparison between groups of annual rate of change in the area of GA as measured by fundus autofluorescence (FAF).

From baseline to last on-treatment visit (48 up to 96 weeks)

次要结果测量

结果测量
措施说明
大体时间
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in photoreceptor degeneration (PRD) in eyes with GA
大体时间:From baseline to last on-treatment visit (48 up to 96 weeks)

Comparison between groups of annual rate of change in the area of PRD as measured by optical coherence tomography (OCT)

From baseline to last on-treatment visit (48 up to 96 weeks)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年1月10日

初级完成 (估计的)

2028年3月30日

研究完成 (估计的)

2028年5月30日

研究注册日期

首次提交

2024年10月23日

首先提交符合 QC 标准的

2024年10月24日

首次发布 (实际的)

2024年10月26日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅